Trade Mark Journal No.2026/010 6 March 2026
WO0000001903593 (5,42)
Office of origin: Israel
Date of International Registration:8 December 2025
Date of designation in the UK:
8 December 2025
International priority date claimed: 18 June 2025
(Israel)
(384522)
- Class 5
- Pharmaceutical preparations for the treatment of degenerative diseases; pharmaceutical preparations, namely cell therapy for the treatment of neurodegenerative diseases; pharmaceutical preparations, namely cell therapy for the treatment of metabolic disorders; pharmaceutical preparations, namely cell therapy for the treatment of diabetes and ALS; pharmaceutical preparations for the treatment of central nervous system disorders; pharmaceutical preparations for the treatment of ALS; pharmaceutical preparations for the treatment of diabetes; pharmaceutical preparations for the treatment of narcolepsy; stem cells for medical purposes; pharmaceutical compositions containing stem cells; pharmaceutical compositions containing stem cells for the treatment of degenerative diseases; pharmaceutical compositions containing stem cells for the treatment of neurodegenerative and metabolic diseases.
- Class 42
- Research and development services in the field of biotechnology; research and development services in the field of pharmaceutical preparations; research and development services in the field of stem cells; research and development services in the field of cell therapy; research and development of induced pluripotent stem cells; research and development services in the field of pharmaceutical preparations, namely research and development of proprietary cell lines for the treatment of diabetes and ALS; research and development services in the field of pharmaceutical preparations, namely research and development of pluripotent stem cells for the treatment of neurodegenerative and metabolic diseases; scientific research in the medical and pharmaceutical field, and consultancy and information relating thereto; design and development of technology for cell therapy for the treatment of degenerative diseases; pharmaceutical drug development services; development of products for others in the field of pharmaceuticals; scientific services relating to processing human cells; medical and scientific research and development of human stem cells; scientific and technological services in the field of regenerative medicine; scientific and technological services and research and development relating thereto in the field of stem cell-based regenerative therapies for the treatment of neurodegeneration and metabolic disorders; medical and scientific research and development in the field of regenerative medicine; pharmaceutical research and development services in the field of cell regeneration and engineering.
KADIMASTEM LTD.
Representative: G.E. Ehrlich (1995) Ltd., Hamasger 35, Sky Tower, 13 Fl. St., 6721407 Tel Aviv- Yafo, ISRAEL